Brian K Link Selected Research

Therapeutics

12/2023	Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.
11/2023	Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
11/2023	Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study.
1/2023	Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
12/2022	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
11/2022	Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.
4/2022	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
1/2022	Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis.
1/2021	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival.
1/2021	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brian K Link Research Topics

Disease

34	Lymphoma (Lymphomas) 06/2024 - 02/2002
31	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 11/2023 - 10/2007
22	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2019 - 02/2002
21	Neoplasms (Cancer) 01/2024 - 02/2002
17	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 03/2010
10	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2017 - 03/2005
8	Hodgkin Disease (Hodgkin's Disease) 01/2020 - 04/2006
6	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 03/2004
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2023 - 11/2013
4	Neutropenia 01/2011 - 05/2005
3	Infections 01/2016 - 10/2010
2	Fatigue 01/2022 - 03/2012
2	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 04/2020 - 12/2010
2	Leukemia 01/2020 - 04/2008
2	Hematologic Neoplasms (Hematological Malignancy) 11/2017 - 01/2016
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2016 - 05/2015
2	Febrile Neutropenia 04/2006 - 03/2003
1	Disease Progression 01/2023
1	Herpes Zoster 12/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2022
1	IgA Deficiency 11/2020
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2020
1	Autoimmune Diseases (Autoimmune Disease) 10/2019
1	Inflammation (Inflammations) 10/2019
1	Testicular Neoplasms (Testicular Cancer) 01/2018
1	Follicular Mucinosis 04/2017
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2017
1	Necrosis 01/2017
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2016
1	Multiple Myeloma 01/2016
1	Urinary Bladder Neoplasms (Bladder Cancer) 12/2015

Drug/Important Bio-Agent (IBA)

28	Rituximab (Mabthera)FDA Link 12/2022 - 02/2002
10	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 03/2003
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 03/2003
9	Vincristine (Oncovin)FDA LinkGeneric 01/2020 - 03/2003
9	Prednisone (Sone)FDA LinkGeneric 01/2020 - 03/2003
8	Monoclonal AntibodiesIBA 01/2015 - 02/2002
7	AnthracyclinesIBA 01/2019 - 06/2010
6	CytokinesIBA 08/2017 - 12/2012
5	ProMune (CpG 7909)IBA 07/2013 - 09/2006
4	AntigensIBA 10/2019 - 02/2002
4	Complement System Proteins (Complement)IBA 02/2017 - 06/2008
3	Dihydrotachysterol (AT 10)IBA 01/2022 - 10/2019
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2019 - 06/2008
3	Vitamin D FDA LinkGeneric 11/2017 - 09/2010
3	Immunoglobulins (Immunoglobulin)IBA 12/2014 - 12/2011
3	OligodeoxyribonucleotidesIBA 07/2013 - 03/2005
3	Bleomycin (Blenoxane)FDA LinkGeneric 05/2012 - 04/2006
3	Vinblastine (Vinblastine Sulfate)FDA Link 05/2012 - 04/2006
3	Dacarbazine (DIC)FDA LinkGeneric 05/2012 - 04/2006
3	CPG-oligonucleotideIBA 02/2012 - 03/2005
3	epratuzumabIBA 10/2011 - 02/2002
2	Biological FactorsIBA 01/2024 - 09/2012
2	Alkylating AgentsIBA 11/2023 - 04/2022
2	Bendamustine Hydrochloride FDA Link 12/2022 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2017
2	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 11/2017
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2018 - 10/2014
2	fludarabineIBA 05/2015 - 10/2010
2	ocaratuzumabIBA 01/2015 - 03/2012
2	Alemtuzumab (Campath)FDA Link 07/2014 - 10/2010
2	ofatumumab FDA Link 04/2012 - 06/2008
2	hydroxide ionIBA 02/2011 - 09/2010
2	Toll-Like Receptor 9IBA 12/2010 - 10/2007
2	Immunoconjugates (Immunoconjugate)IBA 02/2002 - 02/2002
2	Humanized Monoclonal AntibodiesIBA 02/2002 - 02/2002
2	apolizumabIBA 02/2002 - 02/2002
1	tisagenlecleucelIBA 11/2022
1	Chimeric Antigen ReceptorsIBA 11/2022
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Immunoglobulin E (IgE)IBA 11/2020
1	ORALIT (ORS)IBA 01/2020
1	Hemoglobins (Hemoglobin)IBA 01/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019
1	lipid-associated sialic acid (LASA)IBA 12/2018
1	Formaldehyde (Formol)FDA Link 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	ParaffinIBA 01/2018
1	CalciumIBA 11/2017
1	ElementsIBA 04/2017
1	obinutuzumabIBA 02/2017
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2016
1	RNA (Ribonucleic Acid)IBA 01/2016
1	cyclo(Arg-Pro) (CI 4)IBA 12/2015
1	Transcription Factors (Transcription Factor)IBA 05/2015
1	ChemokinesIBA 02/2015
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 02/2015
1	purineIBA 07/2014

Therapy/Procedure

45	Therapeutics 12/2023 - 03/2003
19	Drug Therapy (Chemotherapy) 06/2024 - 03/2003
6	Immunotherapy 06/2024 - 02/2002
1	Retreatment 01/2022
1	Cell Transplantation 01/2022
1	Aftercare (After-Treatment) 04/2020
1	Secondary Prevention 01/2018
1	Induction Chemotherapy 01/2018
1	Autologous Transplantation 01/2018
1	Stem Cell Transplantation 10/2017
1	Breast Implants (Breast Implant) 01/2017